Biotechnology firm adopts NewCardio QTinno
The new solution, QTinno is intended to be used for an upcoming Thorough QT trial. According to the company, QTinno 3-D ECG software technology is a novel, fully
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.
The rhFSH analog is developed through Trophogen’s proprietary superagonist hormone technology platform originally licensed from the National Institutes of Health. The contract manufacturing deal includes the technology transfer